These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 19889885

  • 21. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
    Rowland Yeo K, Walsky RL, Jamei M, Rostami-Hodjegan A, Tucker GT.
    Eur J Pharm Sci; 2011 Jun 14; 43(3):160-73. PubMed ID: 21540107
    [Abstract] [Full Text] [Related]

  • 22. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
    Tomkinson HK, Kemp JV, Wollseifen T, Morris T, Oliver SD.
    Clin Ther; 2010 Jul 14; 32(7):1372-86. PubMed ID: 20678684
    [Abstract] [Full Text] [Related]

  • 23. Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects.
    Dhuria S, Einolf H, Mangold J, Sen S, Gu H, Wang L, Cameron S.
    J Clin Pharmacol; 2013 Jun 14; 53(6):642-53. PubMed ID: 23585187
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
    Li X, Junge L, Taubert M, von Georg A, Dahlinger D, Starke C, Frechen S, Stelzer C, Kinzig M, Sörgel F, Jaehde U, Töx U, Goeser T, Fuhr U.
    J Clin Pharmacol; 2020 Sep 14; 60(9):1237-1253. PubMed ID: 32427354
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes.
    Chapron B, Risler L, Phillips B, Collins C, Thummel K, Shen D.
    J Pharm Pharm Sci; 2015 Sep 14; 18(1):101-11. PubMed ID: 25877445
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation.
    Vanhove T, Annaert P, Knops N, de Loor H, de Hoon J, Kuypers DRJ.
    Basic Clin Pharmacol Toxicol; 2019 Jan 14; 124(1):50-55. PubMed ID: 29989304
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.
    Boulenc X, Nicolas O, Hermabessière S, Zobouyan I, Martin V, Donazzolo Y, Ollier C.
    Eur J Drug Metab Pharmacokinet; 2016 Feb 14; 41(1):45-54. PubMed ID: 25374256
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.